TY - JOUR
T1 - Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseases
AU - Cavazzana, I.
AU - Ceribelli, A.
AU - Cattaneo, R.
AU - Franceschini, F.
PY - 2008/12
Y1 - 2008/12
N2 - Objective: To describe the clinical and immunologic features of 6 patients with rheumatic disease and Hepatitis C Virus (HCV) chronic infection, treated with anti-TNF alpha drugs. Patients and methods: Six patients, with repeated positive serology for HCV infection, were affected by Rheumatoid arthritis (RA) (4 cases), Psoriatic Arthritis (PsA) and Polymyositis in one case each. They started anti-TNFalpha treatment (Etanercept), due to a previous failure of combination of different immunosuppressants (Methotrexate, Sulfasalazine, Cyclosporine, Hydroxychloroquine). Results: Patients (3 female and 3 males) showed a mean age at disease onset of 50.6 years (SD 14.5) and a mean disease duration of 12.5 years (SD: 8.8). Etanercept (dosage of 50 mg weekly) was continued for a median period of 14 months. Patients affected by RA and PsA achieved a good clinical response, with a significant reduction of DAS28 during treatment (p: 0.0001). No patient received any specific therapy for HCV infection. Elevated HCV-RNA titres were recorded in 5 cases at start of Etanercept. No significant increase was observed during anti-TNF alpha treatment. No cases of hepatic failure were recorded. Conclusion: Anti-TNF alpha therapy showed to be effective, safe and well tolerated in the setting of HCV infection.
AB - Objective: To describe the clinical and immunologic features of 6 patients with rheumatic disease and Hepatitis C Virus (HCV) chronic infection, treated with anti-TNF alpha drugs. Patients and methods: Six patients, with repeated positive serology for HCV infection, were affected by Rheumatoid arthritis (RA) (4 cases), Psoriatic Arthritis (PsA) and Polymyositis in one case each. They started anti-TNFalpha treatment (Etanercept), due to a previous failure of combination of different immunosuppressants (Methotrexate, Sulfasalazine, Cyclosporine, Hydroxychloroquine). Results: Patients (3 female and 3 males) showed a mean age at disease onset of 50.6 years (SD 14.5) and a mean disease duration of 12.5 years (SD: 8.8). Etanercept (dosage of 50 mg weekly) was continued for a median period of 14 months. Patients affected by RA and PsA achieved a good clinical response, with a significant reduction of DAS28 during treatment (p: 0.0001). No patient received any specific therapy for HCV infection. Elevated HCV-RNA titres were recorded in 5 cases at start of Etanercept. No significant increase was observed during anti-TNF alpha treatment. No cases of hepatic failure were recorded. Conclusion: Anti-TNF alpha therapy showed to be effective, safe and well tolerated in the setting of HCV infection.
KW - Anti-TNF alpha
KW - Etanercept
KW - HCV infection
KW - Polymyositis
KW - Rheumatoid arthritis
UR - http://www.scopus.com/inward/record.url?scp=56349159321&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=56349159321&partnerID=8YFLogxK
U2 - 10.1016/j.autrev.2008.05.002
DO - 10.1016/j.autrev.2008.05.002
M3 - Article
C2 - 19014870
AN - SCOPUS:56349159321
VL - 8
SP - 104
EP - 106
JO - Autoimmunity Reviews
JF - Autoimmunity Reviews
SN - 1568-9972
IS - 2
ER -